Department of Pharmacy, University of Genoa, Viale Benedetto XV n. 3, 16132, Genoa, Italy.
Department of Pharmacy, University of Genoa, Viale Benedetto XV n. 3, 16132, Genoa, Italy.
Eur J Med Chem. 2018 Feb 25;146:171-184. doi: 10.1016/j.ejmech.2018.01.059. Epub 2018 Feb 4.
The design of novel chemical classes acting towards several G-protein-coupled receptors (GPCRs) represents a leading strategy in drug discovery, aimed at deriving effective and safe candidates for further assessment. During the last years, TAAR1 arose as a promising druggable target in medicinal chemistry, being of interest in the treatment of several pathologies, such as neuropsychiatric disorders, type 2 diabetes and obesity. Nevertheless, the limited number of known potent and selective ligands and the species-specificity responsiveness exhibited by those derivatives nowadays available make the discovery of novel compounds a challenging task. Herein, we discuss the development of two quantitative-structure activity relationship (QSAR) models around the agonism ability experienced by different chemo-types toward murine and human TAAR1 (m/hTAAR1) with the aim at deciphering some clues involved in their species-specificity responsiveness. Qualitatively, these information were evaluated guiding for the synthesis of novel ligands, which proved to feature selective agonism ability with respect to the mTAAR1 and hTAAR1 orthologues.
新型化学类药物作用于几种 G 蛋白偶联受体(GPCR)的设计代表了药物发现的主要策略,旨在为进一步评估开发出有效和安全的候选药物。近年来,TAAR1 在药物化学中作为一个有前途的可成药靶点出现,对于治疗多种疾病(如神经精神障碍、2 型糖尿病和肥胖症)具有重要意义。然而,目前已知的有效和选择性配体数量有限,以及这些衍生物表现出的种属特异性反应性,使得发现新型化合物成为一项具有挑战性的任务。本文讨论了两种定量构效关系(QSAR)模型的发展,这些模型围绕着不同化学类型对鼠和人 TAAR1(m/hTAAR1)的激动能力,旨在破译它们种属特异性反应性所涉及的一些线索。从定性的角度来看,这些信息的评估为新型配体的合成提供了指导,这些配体被证明对 mTAAR1 和 hTAAR1 同源物具有选择性激动作用。